Clinical trials since 2022
| Date | Country | Disease | Title | Phase | Status | +info |
|---|---|---|---|---|---|---|
|
10/2023 |
|
PSA |
a Prospective, Randomized, Controlled, Open Label, Assessor-Blinded, Parallel-Group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy in a Treat-to-Target Approach on Maintaining Minimal Disease Activity in Adult Subjects with Psoriatic Arthritis. |
III/IV |
|
|
|
06/2023 |
|
Both |
Safety and immunologic response of shingrix vaccination in patients suffering from psoriasis or psoriatic arthritis shivap. |
II |
|
|
|
04/2023 |
|
Psoriasis |
An Investigator-Initiated, Phase 4, Open-Label, Single-Arm, Single-Center Study Investigating the Tissue-Resident Memory t-Cells and Disease Memory in Psoriasis Skin During Guselkumab Treatment. the Gusmem Study. |
IV |
|
|
|
03/2023 |
|
PSA |
Vtx958 versus placebo for the treatment of active psoriatic arthritis. |
II |
|
|
|
03/2023 |
|
Psoriasis |
A research study to evaluate if vtx958, a test medicine, not yet approved for doctors to prescribe, is safe and will help in the treatment of psoriasis. |
II |
|
|
|
01/2023 |
|
Psoriasis |
A study to evaluate esk-001 in patients with psoriasis. |
II |
|
|
|
01/2023 |
|
PSA |
Apremilast study in children with active oral ulcers associated with behets disease or juvenile psoriatic arthritis. |
III |
|
|
|
11/2022 |
|
PSA |
Study to evaluate the efficacy, pharmacokinetics, safety, and immunogenicity of subcutaneously administered ustekinumab or guselkumab in pediatric participants with active juvenile psoriatic arthritis. |
III |
|
|
|
11/2022 |
|
PSA |
Evaluation of sonelokimab in patients with active psoriatic arthritis. |
II |
|
|
|
10/2022 |
|
Psoriasis |
Efficacy and safety of deucravacitinib versus placebo in participants with moderate-to- severe scalp psoriasis. |
IV |
|
|
|
10/2022 |
|
Psoriasis |
Comparison of the efficacy and safety between two study drugs in skin disease patients. |
III |
|
|
|
10/2022 |
|
PSA |
A phase 2a, randomized, double-blind, placebo- controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of zunsemetinib vs placebo in patients with moderate-to-severe active psoriatic arthritis. |
II |
|
|
|
09/2022 |
|
Psoriasis |
A study to compare pharmacokinetics, efficacy, and safety of ct-p17 with humira in patients with moderate to severe chronic plaque psoriasis. |
III |
|
|
|
08/2022 |
|
Psoriasis |
Hulio interchangeability to humira, comparing pharmacokinetics, efficacy, safety and immunogenicity. |
III |
|
|
|
07/2022 |
 Estonia Latvia |
Psoriasis |
Bmab 1200 versus stelara in patients with moderate to severe chronic plaque psoriasis. |
III |
|
|
|
07/2022 |
|
Psoriasis |
A study to evaluate the efficacy, safety, and tolerability of an oral tablet formulation of jnj- 77242113 for the treatment of moderate-to-severe plaque psoriasis. |
II |
|
|
|
06/2022 |
|
Psoriasis |
A long-term extension study of jnj-77242113 in participants with moderate-to-severe plaque psoriasis. |
II |
|
|
|
03/2022 |
|
PSA |
Identification of synovial biomarkers of response to ixekizumab in refractory psoriatic arthritis. |
IV |
|
|
|
03/2022 |
|
Psoriasis |
A study to investigate the safety and efficacy of multiple doses of jnj-77242113 in participants with moderate to severe plaque psoriasis. |
II |
|
Ongoing*Date
Country
10/2023
Germany
Disease
Title
PSA
a Prospective, Randomized, Controlled, Open Label, Assessor-Blinded, Parallel-Group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy
in a Treat-to-Target Approach on Maintaining Minimal Disease Activity in Adult Subjects with
Psoriatic Arthritis.
Phase
Status
+info
Date
Country
06/2023
Germany
Disease
Title
Both
Safety and immunologic response of shingrix vaccination in patients suffering from psoriasis or psoriatic arthritis shivap.
Phase
Status
+info
Date
Country
04/2023
Denmark
Disease
Title
Psoriasis
An Investigator-Initiated, Phase 4, Open-Label, Single-Arm, Single-Center Study Investigating the Tissue-Resident Memory t-Cells and Disease Memory in Psoriasis Skin During Guselkumab Treatment. The Gusmem Study.
Phase
Status
+info
Date
Country
03/2023
Bulgaria
Czech Republic
Germany
Hungary
Spain
Disease
Title
PSA
Vtx958 versus placebo for the treatment of active psoriatic arthritis.
Phase
Status
+info
Date
Country
03/2023
Poland
Disease
Title
Psoriasis
A research study to evaluate if vtx958, a test medicine, not yet approved for doctors to prescribe, is safe and will help in the treatment of psoriasis.
Phase
Status
+info
Date
Country
01/2023
Czech Republic
Poland
Disease
Title
Psoriasis
A study to evaluate esk-001 in patients with psoriasis.
Phase
Status
+info
Date
Country
01/2023
France
Greece
Italy
Spain
Disease
Title
PSA
Apremilast study in children with active oral ulcers associated with behets disease or juvenile psoriatic arthritis.
Phase
Status
+info
Date
Country
11/2022
Denmark
France
Germany
Netherlands
Poland
Spain
Disease
Title
PSA
Study to evaluate the efficacy, pharmacokinetics, safety, and immunogenicity of subcutaneously administered ustekinumab or guselkumab in pediatric participants with active juvenile psoriatic arthritis.
Phase
Status
+info
Date
Country
11/2022
Bulgaria
Czech Republic
Hungary
Spain
Disease
Title
PSA
Evaluation of sonelokimab in patients with active psoriatic arthritis.
Phase
Status
+info
Date
Country
10/2022
Germany
Disease
Title
Psoriasis
Efficacy and safety of deucravacitinib versus placebo in participants with moderate-to-severe scalp psoriasis.
Phase
Status
+info
Date
Country
10/2022
Hungary
Disease
Title
Psoriasis
Comparison of the efficacy and safety between two study drugs in skin disease patients.
Phase
Status
+info
Date
Country
10/2022
Poland
Disease
Title
PSA
A phase 2a, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of zunsemetinib vs placebo in
patients with moderate-to-severe active psoriatic arthritis.
Phase
Status
+info
Date
Country
09/2022
Estonia
Disease
Title
Psoriasis
A study to compare pharmacokinetics, efficacy, and safety of ct-p17 with humira in patients with moderate to severe chronic plaque psoriasis.
Phase
Status
+info
Date
Country
08/2022
Bulgaria
Czech Republic
Estonia
Poland
Disease
Title
Psoriasis
Hulio interchangeability to humira, comparing pharmacokinetics, efficacy, safety and immunogenicity.
Phase
Status
+info
Date
Country
07/2022
Estonia
Latvia
Disease
Title
Psoriasis
Bmab 1200 versus stelara in patients with moderate
to severe chronic plaque psoriasis.
Phase
Status
+info
Date
Country
07/2022
Spain
Disease
Title
Psoriasis
A study to evaluate the efficacy, safety, and tolerability of an oral tablet formulation of jnj-77242113 for the treatment of moderate-to-severe plaque psoriasis.
Phase
Status
+info
Date
Country
06/2022
Germany
Poland
Spain
Disease
Title
Psoriasis
A long-term extension study of jnj-77242113 in participants with moderate-to-severe plaque psoriasis.
Phase
Status
+info
Date
Country
03/2022
Italy
Disease
Title
PSA
Identification of synovial biomarkers of response to
ixekizumab in refractory psoriatic arthritis.
Phase
Status
+info
Date
Country
03/2022
Spain
Disease
Title
Psoriasis
A study to investigate the safety and efficacy of multiple doses of jnj-77242113 in participants with moderate to severe plaque psoriasis.